Long term study of Eloctate confirms safety and efficacy in haemophilia A.- Orphan Biovitrum.
Orphan Biovitrum announced the final results of ASPIRE the most comprehensive long-term studies of extended half-life factor therapies in haemophilia A. The data confirm the established safety and sustained efficacy of Elocta (efmoroctocog alfa), marketed as Eloctate in the United States and other countries over four years of treatment in previously treated adult, adolescent, and paediatric patients with severe haemophilia A.
ASPIRE is an open-label, non-randomised, multi-year extension study for people who completed the pivotal, phase III A-LONG or Kids A-LONG studies. The primary endpoint is the development of inhibitors. Key findings include the fact that overall median annualised bleed rates (ABRs) for those on prophylactic treatment remained low throughout ASPIRE, particularly in the individualised dosing arm. Zero spontaneous joint bleeds were reported in subjects in all age groups in the individualised dosing arm. Median joint ABRs of below 0.66 were also reported in the cohort.
In the study, adult and adolescent subjects (n=72) treated prophylactically with efmoroctocog alfa experienced a mean improvement in modified hemophilia joint health (mHJHS) score of -2.5 (negative shows improvement) compared to baseline score in A-LONG. Over 92 per cent of subjects either lengthened or experienced no change in dosing intervals during the length of the study. Low ABRs as well as improved joint health scores reported in ASPIRE demonstrate clinical benefit of efmoroctocog alfa that goes beyond just bleed prevention. These results were presented at the 60th Annual Meeting of the American Society of Hematology (ASH).
Comment: Elocta was approved in the EU on 25 November 2015 and by the FDA as Eloctate on 6 June 2014.
Related news and insights
AbbVie has announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (Skyrizi 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Merck Inc., announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year.
Merck Inc., and Eisai announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima (marketed as Kisplyx in the European Union [EU]) for the treatment of advanced renal cell carcinoma [RCC]), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.